Published Date: 09 Dec 2024
Two-thirds of phase II patients had a complete response at 12 weeks of treatment
Read Full NewsResearchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and most comprehensive molecular analysis of renal medullary carcinoma (RMC), a rare and aggressive ...
The U.S. Food and Drug Administration approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.
1.
Adjuvant ICIs: A Winner and a Loser in Clear Cell Renal Cell Carcinoma?
2.
Study opens up possibility of bespoke prostate cancer treatment
3.
Having dense breasts is linked to cancer, but advice about breast density can depend on where you live
4.
What does it mean for Biden's prostate cancer to be 'aggressive'? A urologic surgeon explains
5.
Rural residents continue to have higher odds of skin cancer, study finds
1.
Asymptomatic Thrombocytopenia: Unraveling the Enigma of Low Platelet Counts Without Symptoms
2.
Hope for a Cure: Exploring New Treatments for Sickle Cell Anemia
3.
Personalized Cancer Vaccines: The Next Frontier in Precision Oncology
4.
Optimizing the Diagnosis and Treatment of Hematological Diseases Through Artificial Intelligence
5.
Unlocking the Potential of Hemin: A Novel Approach to Health and Wellbeing
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
3.
Navigating the Complexities of Ph Negative ALL - Part X
4.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
5.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation